Publications by authors named "David Mutimer"

Claim this Profile
P
Peer-Delivered Outreach With Rapid Treatment Pathways for Hepatitis C Testing and Treatment Among Unhoused People.
Gabriele Vojt, Philippe Bonnet, Jennifer Scott, Emma Hathorn, Lisa Ellis, David Mutimer

J Viral Hepat· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient Source of Referral Is a Key Determinant of Subsequent Retention in Care for Young Chronic Hepatitis B Patients.
David Mutimer, Maxine Brown, Jacqueline Logan, Chayarani Kelgeri

J Viral Hepat· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Determinants of HBeAg loss during follow-up of a multiethnic pediatric cohort.
David Mutimer, Sowsan F Atabani, Maxine Brown, Jacqueline Logan, Chayarani Kelgeri

J Med Virol· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rate and determinants of antiviral treatment initiation for patients with HBeAg-negative chronic hepatitis B.
David Mutimer, Ahmed Elsharkawy, Emma Hathorn, Selvi Arunkumar

J Viral Hepat· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mortality rates among patients successfully treated for hepatitis C in the era of interferon-free antivirals: population based cohort study.
Victoria Hamill, Stanley Wong, Jennifer Benselin, Mel Krajden, Peter C Hayes, David Mutimer

BMJ· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Age, ethnicity and proximity to clinic determine retention in care of chronic hepatitis B patients.
David Mutimer, Ahmed Elsharkawy, Emma Hathorn, Selvi Arunkumar

J Viral Hepat· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hepatitis B e antigen and e antibody in a multi-ethnic cohort of adult chronic hepatitis B virus patients followed at a single liver unit for a period of 20 years.
David Mutimer, Ahmed Elsharkawy, Emma Hathorn, Selvi Arunkumar

J Viral Hepat· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-World Outcomes of Direct-Acting Antiviral Treatment and Retreatment in United Kingdom-Based Patients Infected With Hepatitis C Virus Genotypes/Subtypes Endemic in Africa.
Elihu Aranday-Cortes, C Patrick McClure, Christopher Davis, William L Irving, Kazeem Adeboyejo, David Mutimer

J Infect Dis· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An experience using historical hepatitis C data to Re-Engage: Possibilities and pitfalls during the COVID-19 pandemic.
William Osborne, Noorann Sheikh, Gemma Botterill, Sally Bufton, David Mutimer

Public Health Pract (Oxf)· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High Sustained Virologic Response Rates of Glecaprevir/Pibrentasvir in Patients With Dosing Interruption or Suboptimal Adherence.
Philippe J Zamor, Ashley Brown, Douglas E Dylla, John F Dillon, Anne F Luetkemeyer, David Mutimer

Am J Gastroenterol· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of direct-acting antiviral agents on liver function in patients with chronic hepatitis C virus infection.
Philip J Johnson, Sarah Berhane, Alex J Walker, Fiona H Gordon, Steven D Ryder, David Mutimer

J Viral Hepat· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Controversies regarding shielding and susceptibility to COVID-19 disease in liver transplant recipients in the United Kingdom.
Angus John Hann, Hanns Lembach, Siobhan C McKay, Moira Perrin, John Isaac, David Mutimer

Transpl Infect Dis· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
English hepatitis C registry data show high response rates to directly acting anti-virals, even if treatment is not completed.
Kathryn Drysdale, Yevedzo Ntuli, Jonathan Bestwick, William Gelson, Kosh Agarwal, David Mutimer

Aliment Pharmacol Ther· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of HIV and chronic kidney disease comorbidities on hepatitis C treatment choices, drug-drug interactions and hepatitis C cure.
Salamat Ali, Tofeeq Ur-Rehman, Eleri Lougher, David Mutimer, Mashhood Ali

Int J Clin Pharm· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Consensus recommendations for resistance testing in the management of chronic hepatitis C virus infection: Public Health England HCV Resistance Group.
Daniel Bradshaw, Jean L Mbisa, Anna Maria Geretti, Brendan J Healy, Graham S Cooke, David Mutimer

J Infect· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evolution of the burden of active hepatitis C virus infection in England from September 2015 to September 2016: a repeated cross-sectional analysis.
Laure Lacoin, Michael Hurst, Nathan R Hill, Jason Gordon, Anna Maria Geretti, David Mutimer

BMJ Open· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The association between hepatocellular carcinoma and direct-acting anti-viral treatment in patients with decompensated cirrhosis.
Ali Jibran Mecci, Polychronis Kemos, Clifford Leen, Adam Lawson, Paul Richardson, David Mutimer

Aliment Pharmacol Ther· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Glecaprevir/Pibrentasvir in patients with chronic HCV genotype 3 infection: An integrated phase 2/3 analysis.
Steven Flamm, David Mutimer, Armen Asatryan, Stanley Wang, Jürgen Rockstroh

J Viral Hepat· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hepatitis C virus infection is associated with hepatic and adipose tissue insulin resistance that improves after viral cure.
Teegan R Lim, Jonathan M Hazlehurst, Andrei I Oprescu, Matthew J Armstrong, Sewa F Abdullah, David J Mutimer

Clin Endocrinol (Oxf)· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Liver transplant listing for hepatitis C-associated cirrhosis and hepatocellular carcinoma has fallen in the United Kingdom since the introduction of direct-acting antiviral therapy.
Arash Vaziri, Alexander Gimson, Kosh Agarwal, Mark Aldersley, Andrew Bathgate, David Mutimer

J Viral Hepat· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus Infection.
Nancy Reau, Paul Y Kwo, Susan Rhee, Robert S Brown, Kosh Agarwal, David Mutimer

Hepatology· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High SVR12 with 8-week and 12-week glecaprevir/pibrentasvir therapy: An integrated analysis of HCV genotype 1-6 patients without cirrhosis.
Massimo Puoti, Graham R Foster, Stanley Wang, David Mutimer, Edward Gane

J Hepatol· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Elbasvir/grazoprevir and sofosbuvir for hepatitis C virus genotype 3 infection with compensated cirrhosis: A randomized trial.
Graham R Foster, Kosh Agarwal, Matthew E Cramp, Sulleman Moreea, Stephen Barclay, David J Mutimer

Hepatology· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pre- and Post-Transplant Treatment of Viral Hepatitis C.
David Mutimer

Dig Dis· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HIV-Positive-to-HIV-Positive Liver Transplantation.
Emma Hathorn, Erasmus Smit, Ahmed M Elsharkawy, Simon R Bramhall, Sally A Bufton, David Mutimer

N Engl J Med· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis